story of the week
Sacituzumab Govitecan as Second-Line Treatment for Metastatic Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
NPJ breast cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis
NPJ Breast Cancer 2022 Jun 09;8(1)72, LA Carey, D Loirat, K Punie, A Bardia, V Diéras, F Dalenc, JR Diamond, C Fontaine, G Wang, HS Rugo, SA Hurvitz, K Kalinsky, J O'Shaughnessy, S Loibl, L Gianni, M Piccart, Y Zhu, R Delaney, S Phan, J CortésFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.